Get the Stockscreener App
5.19
3.00%
-0.14
Amylyx Pharmaceuticals Inc stock is traded at $5.19, with a volume of 331.27K.
It is down -3.00% in the last 24 hours and up +6.82% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$5.33
Open:
$5.28
24h Volume:
331.27K
Relative Volume:
0.37
Market Cap:
$513.45M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
7.4143
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
-4.61%
1M Performance:
+6.82%
6M Performance:
+31.22%
1Y Performance:
+219.14%
1-Day Range:
$5.10
$5.28
1-Week Range:
$5.10
$5.66
52-Week Range:
$1.62
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
5.195 | 513.45M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
516.55 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.87 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.67 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.72 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Citi initiates Amylyx stock with buy rating on promising pipeline By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Citi initiates Amylyx stock with buy rating on promising pipeline - Investing.com
Amylyx Pharmaceuticals (AMLX): Citigroup Initiates Coverage with 'Buy' Rating | AMLX Stock News - GuruFocus
Amylyx initiated with a Buy at Citi - TipRanks
Amylyx (AMLX) Gains Positive Outlook with New Analyst Coverage | AMLX Stock News - GuruFocus
Diabetes Insipidus Market Statistics Expected to Experience - openPR.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
# H.C. Wainwright reiterates Buy rating on AMYLYX stock ahead of trial - Investing.com India
Optimistic Buy Rating for Amylyx Pharmaceuticals’ AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - ACCESS Newswire
AMX0114 receives FDA fast track status for the treatment of ALS - ALS News Today
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Wellington Management Group LLP Purchases New Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Ameriprise Financial Inc. Purchases Shares of 50,428 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc Holds Annual Stockholder Meeting - TipRanks
Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
FDA fast tracks Amylyx’s ALS drug candidate AMX0114 By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis - BioSpace
Amylyx Pharmaceuticals' Potential ALS Treatment Gets FDA Fast Track Designation - marketscreener.com
Amylyx (AMLX) Gains FDA Fast Track Status for ALS Treatment | AM - GuruFocus
FDA fast tracks Amylyx’s ALS drug candidate AMX0114 - Investing.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Millennium Management LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Northern Trust Corp Purchases 11,214 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals (NASDAQ:AMLX) Now Covered by TD Cowen - Defense World
TD Cowen starts Amylyx stock coverage with Buy rating - Investing.com Australia
Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Pot - GuruFocus
TD Cowen starts Amylyx stock coverage with Buy rating By Investing.com - Investing.com Nigeria
Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Potential | AMLX Stock News - GuruFocus
Amylyx initiated with a Buy at TD Cowen - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - ACCESS Newswire
2025-05-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse
Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com
🌐 ALS Treatment Market to Hit $1.04 Billion by 2032 | Driven by New Drug Approvals & Asia-Pacific Expansion - openPR.com
Man Group plc Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bank of America Corp DE Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences - BioSpace
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bedrosian Camille L | Chief Medical Officer |
Mar 31 '25 |
Sale |
3.47 |
12,425 |
43,082 |
194,375 |
| Mazzariello Gina | Chief Legal Officer |
Mar 31 '25 |
Sale |
3.48 |
9,192 |
31,954 |
187,969 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.47 |
21,490 |
74,482 |
3,355,280 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.46 |
21,490 |
74,454 |
3,355,276 |
| Zeiher Bernhardt G | Director |
Mar 20 '25 |
Buy |
3.70 |
10,000 |
37,005 |
10,000 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.15 |
4,595 |
14,483 |
3,196,648 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.17 |
4,595 |
14,549 |
3,196,652 |
| Mazzariello Gina | Chief Legal Officer |
Mar 03 '25 |
Sale |
3.12 |
1,611 |
5,022 |
133,310 |
| Mazzariello Gina | Chief Legal Officer |
Feb 24 '25 |
Sale |
3.15 |
4,169 |
13,145 |
134,921 |
| Klee Justin B. | Co-Chief Executive Officer |
Feb 05 '25 |
Option Exercise |
1.57 |
36,310 |
57,007 |
3,201,243 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):